Bortezomib and Emetine share 27 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.190 means 19% of the combined target set is bound by both compounds. The IDF-weighted score of 0.129 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Bortezomib and Emetine have in common?
Bortezomib and Emetine share 27 molecular targets with a Jaccard similarity of 19%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Bortezomib and Emetine be combined?
Bortezomib and Emetine share 27 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Bortezomib or Emetine?
Both Bortezomib and Emetine have substantial PubMed research. View their individual profiles for full evidence scores.